Research Report: Zheshang Securities: Maintaining Fosun Pharmaceuticals' “Buy” Rating, Optimistic About the Company's International Implementation
Fosun Pharmaceutical (600196): Optimistic about the continued advancement of internationalization & innovation
Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain
Fosun Pharmaceutical (600196): The deduction of non-profits is in line with expectations, and all lines are expected to accelerate growth
Fosun Pharmaceutical (600196): Performance is in line with expectations, and 2024 ushered in multiple improvements
Damo: Lowering Fosun Pharma's target price to HK$23, in line with the market
Research Report Nuggets | CICC: Maintaining Fosun Pharma's “Outperforming Industry” Rating and Lowering Target Price to HK$27.5
Fosun Pharmaceutical (600196): Pharmaceutical business grows rapidly and innovative achievements continue to be implemented
Fosun Pharmaceuticals (600196): Profit side under pressure in the 2nd quarter, innovative products grew steadily
Fosun Pharmaceutical (600196): COVID-19 base, expenses, etc. disrupt profits, short-term pressure, innovation investment continues to reap
Bank Ratings | Citibank: Launching a 30-day Negative Catalyst for Fosun Pharmaceutical to Observe Earnings Expected in the First Half of the Year
Big Bank Ratings | Credit Suisse Lowers Fosun Pharmaceutical's Target Price Target Price to HK$29 Rating Outperforms Market
Fosun Pharmaceutical (600196): Performance is in line with expectations, new products are growing rapidly after new products
Fosun Pharmaceutical (600196) Company Review: Innovation Drives New Drug Expansion, Clinical Advancement, and BD Go Hand in Hand
Fosun Pharmaceutical (600196): Deducting non-net profits is in line with expectations, innovative research and development continues to advance
Fosun Pharmaceutical (600196): Continuous development and implementation of new drug pipelines, continuous optimization of revenue structure
Fosun Pharmaceutical (600196): Innovation, Transformation, Optimizing Revenue Structure, Performance Maintains Steady Growth
Fosun Pharmaceutical (600196): Pharmaceutical revenue structure optimization and innovation are poised to go
Fosun Pharmaceuticals (600196): Slurizumab's Major Indication Approved to Maintain “Buy” Rating
Fosun Pharmaceutical (600196): Obtaining Hans-like US interests and testing the waters for PD-1 to go overseas
No Data